Clinical Trials

Colonic Neoplasms

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

24 enrolled 14 charts

Phase 1 Active not recruiting

Colonic Neoplasms

NCT05722327 2026-03-04

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

24 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

240 enrolled 14 charts

Colonic Neoplasms, Rectal Neoplasms

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

42 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05040568 2026-01-26

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase 1 Completed

15 enrolled

Phase 2/3 Active not recruiting

Colonic Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms

NCT07318805 2026-01-06

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

46 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT05510895 2025-10-01

NeoBRAF

2 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

731 enrolled 3 FDA

GastrointestinalGynecologic

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00766142 2025-08-29

COCHISE

Phase 2 Terminated

18 enrolled 9 charts

Colonic Neoplasms, Peritoneal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 5 FDA

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT04554836 2025-06-08

MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

6 enrolled 9 charts

Colonic Neoplasms, Rectal Neoplasms

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Colonic Neoplasms, Colorectal Neoplasms

NCT06640166 2025-02-12

ECLYPse

Phase 2 Recruiting

25 enrolled

Phase 3 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT04793958 2025-02-11

KRYSTAL-10

461 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01167725 2024-12-27

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Phase 3 Terminated

340 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06575127 2024-08-28

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

Phase 2 Recruiting

60 enrolled

Colonic Neoplasms, Neoplasms

NCT05022030 2024-03-07

CAPCET

Phase 2 Recruiting

150 enrolled

Colonic Neoplasms

NCT00079066 2023-08-04

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

572 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

750 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01079780 2023-06-28

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

136 enrolled 13 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04189055 2023-06-12

CETIDYL

Phase 2 Unknown

72 enrolled

Colonic Neoplasms

NCT05278351 2023-03-31

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Phase 2 Unknown

87 enrolled

Colonic Neoplasms

NCT01001377 2022-09-21

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

1,010 enrolled 22 charts

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT05155124 2022-09-13

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Phase 1 Unknown

6 enrolled

Colonic Neoplasms

NCT03524820 2022-08-04

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Phase 2 Terminated

3 enrolled

Colonic Neoplasms

NCT00193219 2022-01-11

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

36 enrolled 8 charts

Colonic Neoplasms

NCT05074966 2021-10-12

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Phase 3 Unknown

314 enrolled

Colonic Neoplasms

NCT00640081 2021-09-22

Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer

169 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01280643 2021-03-15

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase NA Terminated

3 enrolled 8 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00265811 2020-11-09

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

2,559 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT03608046 2020-10-22

AVETUXIRI

Phase 2 Unknown

59 enrolled

Colonic Neoplasms

NCT00079274 2020-05-13

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

3,397 enrolled 24 charts

Colonic Neoplasms

NCT00265850 2020-05-07

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

2,334 enrolled 9 charts